CA Lenvanib 10mg capsule  uses are the following conditions:

• Certain types of advanced thyroid cancer
• Advanced Liver cancer
• Certain types of kidney cancer
• Endometrial cancer

CA Lenvanib 10mg Capsule blocks the enzyme receptor tyrosine kinases (RTKs). RTKs develop new blood vessels that supply oxygen and nutrients to the cells and help them grow. This medicine inhibits the receptors that facilitate the growth of blood vessels in tumor cells. RTKs are present in high concentrations in cancer cells, and administration of this medicine slows down the rate of cancer cells’ growth and multiplication.

Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with CA Lenvanib 10mg Capsule and reduce effectiveness by causing undesirable side effects.

Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with CA Lenvanib 10mg Capsule and reduce effectiveness by causing undesirable side effects.

CA Lenvanib 10mg Capsule is an oral medication that is usually taken once a day, at approximately the same time each day, with or without food. It should be taken as prescribed by a doctor or other healthcare provider. These capsules should be swallowed whole with a glass of water. They should not be crushed, chewed, or opened, as this can affect the way the medication is absorbed and decrease its effectiveness. You should not take a double dose to make up for the second dose.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.

Serious:

• Feeling numb or weak on one side of the body
• Severe headache
• Fever
• Confusion
• Difficulty speaking
• Vision changes
• Dizziness
• Chest pain or pressure
• Pain in arms, jaw, neck, and back
• Breathing problems
• Severe stomach pain
• Blood clot formation
• Blood in stools or coughing blood
• Liver problems
• Pain or soreness in the mouth, teeth, or jaw

Common:

• High or low BP
• Loss of appetite
• Nausea, vomiting, constipation, diarrhea, or indigestion
• Tiredness
• Hoarse voice
• Leg swelling
• Rashes
• Pain in joints or muscles
• Hair loss
• Sleeplessness
• Protein in urine, frequent urination
• Low potassium, magnesium, and calcium levels in the blood
• Dehydration
• Skin problems
• Gall bladder inflammation
• Increase in the values of cholesterol, thyroid-stimulating hormone, digestive enzymes
• Delayed wound healing

• Maintain close communication with your healthcare provider and report any side effects or concerns promptly.

• Avoid pregnancy and breastfeeding during treatment; use effective contraception while taking Lenvanib 10mg Capsule and for at least two weeks after stopping.

• Avoid grapefruits, as they can affect the absorption of this medication.

• Not for children; these capsules should not be given to pediatric patients.

• Protect your skin: use sunscreen and wear protective clothing while outdoors.

• Avoid strenuous activities or exercise until you understand how the medication affects you.

• Maintain a healthy, balanced diet during treatment to support overall health and well-being.

1. Eisai Europe Limited, Electronic Medicines Compendium (EMC), [Revised on Mar 2021] [Accessed on 20th April 2023], https://www.medicines.org.uk/emc/files/pil.6840.pdf
2. Suyama and Iwase, Lenvatinib: A promising molecular targeted agent for multiple cancers, Cancer Control, 2018, 25, 1-5, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056795/pdf/4/1177 473274818789361.pdf
3. Q.M. Anstee, D.E.J. Jones, Liver and Biliary Tract Disease, Davidson’s Principles and Practice of Medicine, 22nd Edition, 2014, 921-988.
4. M.W.J. Strachan, J. Newell-Price, Endocrine disease, Davidson’s Principles & Practice of Medicine, 22nd Edition, 2014, 733-796.
5. Eisai Inc U.S Food and Safety Drug Administration (FDA) [Last revised Aug 2018], [Accessed on 20th April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206947s007lbl.pdf